Charcot Marie Tooth Disease Epidemiology Forecast

DelveInsight’s ‘Charcot–Marie–Tooth Disease—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Charcot–Marie–Tooth Disease, historical and forecasted epidemiology as well as the Charcot–Marie–Tooth Disease trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Charcot–Marie–Tooth Disease Disease Understanding

Charcot–Marie–Tooth Disease is a disease of the peripheral nerves that control muscles – unlike the muscular dystrophies, which affect the muscles themselves. It is a group of genetically heterogeneous disorders that affect the motor and/or peripheral sensory nerves, resulting in muscle weakness and atrophy in addition to sensory loss. Specific gene mutations are responsible for the abnormal function of the peripheral nerves. The nerve cells in individuals with this disorder cannot send electrical signals properly because of abnormalities in the nerve axon or abnormalities in the insulation (myelin) around the axon. Distal legs followed by hands are some of the first locations which exhibit such manifestations. CMT can be inherited in an autosomal dominant, autosomal recessive, or X-linked mode of inheritance and is also known as hereditary motor and sensory neuropathy (HMSN).

Continued in the report…..

Charcot–Marie–Tooth Disease Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Charcot–Marie–Tooth Disease, Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease, Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease, Type-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease, and Age-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Charcot–Marie–Tooth Disease Detailed Epidemiology Segmentation

  • The total prevalent population of Charcot Marie Tooth disease (CMT) in seven major markets was estimated to be 263,835 in 2020 and is anticipated to increase in 2030.
  • The estimates suggest a higher diagnosed prevalence of CMT in the United States with 95,221 diagnosed cases in 2020 that might increase in 2030.
  • As per the analysis, higher number of males were affected by this disease, which is equivalent to the total of 52,372 cases in the US, in 2020.
  • The most common type of CMT is CMT1. CMT1 is further subcategorized into different subtypes that include, CMT1A, CMT1B, CMT1D, etc., and among them, the most common one is CMT1A.
  • CMT prevalence in EU-5 has shown an increasing trend. As per the estimates, EU-5 accounted for a total of 116,794 prevalent cases in 2020. Among EU-5, Germany accounted for a majority of the prevalent cases of CMT in 2020, i.e., 32,291.
  • The age‐specific data revealed that the highest number of people affected with CMT was found in the age group of 41-60 years, while people 0-18 years are least affected in EU-5.
  • The prevalence of CMT in Japan has shown an increasing trend. As per the estimates, Japan accounted for 13,691 prevalent cases of CMT in 2020. 

Scope of the Report

  • The report covers the descriptive overview of Charcot–Marie–Tooth Disease, explaining its causes, symptoms, pathophysiology, and genetic basis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Charcot–Marie–Tooth Disease.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Charcot–Marie–Tooth Disease, Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease, Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease, Type-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease, and Age-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease.

Report Highlights

  • 10-Year Forecast of Charcot–Marie–Tooth Disease 
  • 7MM Coverage
  • Total Prevalent Cases of Charcot–Marie–Tooth Disease 
  • Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease
  • Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease
  • Type-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease
  • Age-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease

Key Questions Answered

  • What are the disease risk, and burden of Charcot–Marie–Tooth Disease?
  • What is the historical Charcot–Marie–Tooth Disease patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Charcot–Marie–Tooth Disease at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Charcot–Marie–Tooth Disease?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Charcot–Marie–Tooth Disease during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Charcot–Marie–Tooth Disease report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Charcot–Marie–Tooth Disease epidemiology forecast.
  • The Charcot–Marie–Tooth Disease epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Charcot–Marie–Tooth Disease epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Executive Summary of Charcot–Marie–Tooth Disease

4. Key Events

5. Charcot–Marie–Tooth: Disease Background and Overview

5.1. Introduction

5.2. Symptoms

5.2.1. Muscle Weakness

5.2.2. Contractures and Bone Deformities

5.2.3. Sensory Loss and Associated Symptoms

5.3. Types of Charcot–Marie–Tooth Disease

5.3.1. CMT Type 1

5.3.2. CMT Type 2

5.3.3. CMT Type 3

5.3.4. CMT Type 4

5.4. Causes

5.5. Genetics and Inheritance

5.5.1. Autosomal Dominant Inheritance

5.5.2. Autosomal Recessive Inheritance

5.5.3. X-Linked Inheritance

5.5.4. Spontaneous Mutation

5.6. Pathophysiology

5.7. Diagnosis

5.7.1. Differential Diagnosis of CMT

5.7.2. Diagnosis Algorithm

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.3. Assumptions and Rationale: 7MM

6.4. Total Prevalent Cases of Charcot–Marie–Tooth Disease in the 7MM

6.5. Total Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the 7MM

6.6. The United States

6.6.1. Total Prevalent Cases of Charcot–Marie–Tooth Disease in the United States

6.6.2. Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the United States

6.6.3. Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the United States

6.6.4. Type-specific Diagnosed Prevalent cases of Charcot–Marie–Tooth Disease in the United States

6.6.5. Age-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the United States

6.7. EU-5

6.7.1. Prevalent Cases of Charcot–Marie–Tooth Disease in EU-5

6.7.2. Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in EU-5

6.7.3. Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in EU-5

6.7.4. Type-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in EU-5

6.7.5. Age-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in EU-5

6.8. Japan

6.8.1. Prevalent Cases of Charcot–Marie–Tooth Disease in Japan

6.8.2. Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in Japan

6.8.3. Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in Japan

6.8.4. Type-specific Diagnosed Prevalent cases of Charcot–Marie–Tooth Disease in Japan

6.8.5. Age-specific Diagnosed Prevalent cases of Charcot–Marie–Tooth Disease in Japan

7. Appendix

7.1. Bibliography

7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Table

Table 1: Summary of Charcot–Marie–Tooth Disease, Epidemiology, and Key Events (2018–2030)

Table 2: Key Events

Table 3: Classification and Genetics of CMT Disease

Table 4: Multidisciplinary Members and Roles in the Diagnosis and Management of CMT

Table 5: Molecular Diagnostic Methods to Detect CMT1A Duplication/HNPP Deletion

Table 6: Summary of CMT Classification, Including Clinical Data (Such as Electrophysiological Results) and Molecular Findings

Table 7: Total Prevalent Cases of Charcot–Marie–Tooth Disease in the 7MM (2018–2030)

Table 8: Total Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the 7MM (2018–2030)

Table 9: Total Prevalent Cases of Charcot–Marie–Tooth Disease in the United States (2018–2030)

Table 10: Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the US (2018–2030)

Table 11: Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the US (2018–2030)

Table 12: Type-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the US (2018–2030)

Table 13: Age-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the US (2018–2030)

Table 14: Prevalent Cases of Charcot–Marie–Tooth Disease in EU-5 (2018–2030)

Table 15: Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in EU-5 (2018–2030)

Table 16: Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in EU-5 (2018–2030)

Table 17: Type-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in EU5 (2018–2030)

Table 18: Age-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in EU5 (2018–2030)

Table 19: Prevalent Cases of Charcot–Marie–Tooth Disease in Japan (2018–2030)

Table 20: Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in Japan (2018–2030)

Table 21: Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in Japan (2018–2030)

Table 22: Type-specific Diagnosed Prevalent cases of Charcot–Marie–Tooth Disease in Japan (2018–2030)

Table 23: Age-specific Diagnosed Prevalent cases of Charcot–Marie–Tooth Disease in Japan (2018–2030)

List of Figures

Figure 1: Patients with CMT Disease

Figure 2: Different Forms of Charcot–Marie–Tooth Disease

Figure 3: Different Forms of Charcot–Marie–Tooth Disease and Associated Genes

Figure 4: Schematic summary showing various Charcot-Marie-Tooth disease (CMT)-related genes and pathways in the peripheral nerve

Figure 5: Diagnostic Protocol for Axonal CMT; Adapted From England et al. (n.d.)

Figure 6: Diagnostic Protocol for Demyelinating CMT; Adapted From England et al. (n.d.)

Figure 7: Diagnostic Protocol of CMT with a Suspected Recessive Inheritance Pattern

Figure 8: An Algorithm for Genetic Testing of CMT Using Clinical and Electrophysiological Features and Disease Subtype-specific NGS Panels

Figure 9: Diagnostic Algorithm in the Patient with CMT

Figure 10: Total Prevalent Cases of Charcot–Marie–Tooth Disease in the 7MM (2018–2030)

Figure 11: Total Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the 7MM (2018–2030)

Figure 12: Total Prevalent Cases of Charcot–Marie–Tooth Disease in the United States (2018–2030)

Figure 13: Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the US (2018–2030)

Figure 14: Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the US (2018–2030)

Figure 15: Type-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the US (2018–2030)

Figure 16: Age-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in the US, (2018–2030)

Figure 17: Prevalent Cases of Charcot–Marie–Tooth Disease in EU-5 (2018–2030)

Figure 18: Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in EU-5 (2018–2030)

Figure 19: Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in EU-5 (2018–2030)

Figure 20: Type-specific Diagnosed Prevalent cases of Charcot–Marie–Tooth Disease in EU-5 (2018-2030)

Figure 21: Age-specific Diagnosed Prevalent cases of Charcot–Marie–Tooth Disease in EU-5 (2018–2030)

Figure 22: Prevalent Cases of Charcot–Marie–Tooth Disease in Japan (2018–2030)

Figure 23: Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in Japan (2018–2030)

Figure 24: Gender-specific Diagnosed Prevalent Cases of Charcot–Marie–Tooth Disease in Japan (2018–2030)

Figure 25: Type-specific Diagnosed Prevalent cases of Charcot–Marie–Tooth Disease in Japan (2018–2030)

Figure 26: Age-specific Diagnosed Prevalent cases of Charcot–Marie–Tooth Disease in Japan (2018–2030)

Figure 27: Patient Journey

  • Tags:
  • Charcot-Marie-Tooth Disease Epidemi...
  • Charcot-Marie-Tooth Disease
  • Charcot-Marie-Tooth Disease Pipeli...
  • Charcot-Marie-Tooth Disease Compan...
  • Charcot-Marie-Tooth Disease preval...
  • Charcot-Marie-Tooth Disease incide...
  • Charcot-Marie-Tooth Disease patien...
  • Charcot-Marie-Tooth Disease treatm...

Forward to Friend

Need A Quote